Chalcogen Attached Indirectly To The Phosphorus By Acyclic Nonionic Bonding Patents (Class 558/169)
  • Patent number: 9879250
    Abstract: There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution. In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 30, 2018
    Assignee: NOF CORPORATION
    Inventors: Fumio Nakashima, Masaru Matsuda, Tomozumi Noda, Satoshi Yamada
  • Patent number: 9795609
    Abstract: A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for the treatment of cardiovascular disease.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: October 24, 2017
    Inventor: Gleb Vladimirovich Zagorii
  • Publication number: 20150144162
    Abstract: A zwitterionic monomer and corresponding cyclopolymerized polyzwitterion (±) (PZ) containing, on each repeating unit, both phosphonate and sulfonate functionalities. Phosphonate ester hydrolysis in PZ gave a pH-responsive polyzwitterionic acid (±) (PZA). The PZA under pH-induced transformation was converted into polyzwitterion/anion (±?) (PZAN) and polyzwitterion/dianion (±=) (PZDAN).
    Type: Application
    Filed: November 27, 2013
    Publication date: May 28, 2015
    Applicants: King Abdulaziz City for Science and Technology, King Fahd University Petroleum and Minerals
    Inventors: Shaikh Asrof ALI, Shamsuddeen Abdullahi Haladu
  • Publication number: 20150080264
    Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Inventors: Francois-Pierre Martin, Ivan Montoliu Roura, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
  • Publication number: 20150065741
    Abstract: The present invention relates to I- and II-type crystals of L-?-glyceryl phosphoryl choline, and to a method for preparing same. More particularly, the present invention relates to noble I- and II-type anhydride crystals of L-?-glyceryl phosphoryl choline, which have a higher purity than conventional liquid L-?-glyceryl phosphoryl choline, and one advantage of which is that formulations and dosages of pharmaceuticals are easily modified, and another advantage of which is that the hygroscopicity of the crystals are much lower than that of conventional polymorphic crystals, providing excellent stability during storage. The present invention also relates to a method for preparing the I- and II-type crystals of L-?-glyceryl phosphoryl choline. The I-type crystal of L-?-glyceryl phosphoryl choline is characterized by having an onset temperature of 147° C. and an absorption peak of 150° C.
    Type: Application
    Filed: July 9, 2014
    Publication date: March 5, 2015
    Inventors: Min-Keun OH, Ki-Nam KIM, Ki-Hyeong SEO, Dae-Gil KWON
  • Patent number: 8927755
    Abstract: The present invention relates to I- and II-type crystals of L-?-glyceryl phosphoryl choline, and to a method for preparing same. More particularly, the present invention relates to noble I- and II-type anhydride crystals of L-?-glyceryl phosphoryl choline, which have a higher purity than conventional liquid L-?-glyceryl phosphoryl choline, and one advantage of which is that formulations and dosages of pharmaceuticals are easily modified, and another advantage of which is that the hygroscopicity of the crystals are much lower than that of conventional polymorphic crystals, providing excellent stability during storage. The present invention also relates to a method for preparing the I- and II-type crystals of L-?-glyceryl phosphoryl choline.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 6, 2015
    Assignee: Hanseochem Co., Ltd.
    Inventors: Min-Keun Oh, Ki-Nam Kim, Ki-Hyeong Seo, Dae-Gil Kwon
  • Publication number: 20140271824
    Abstract: The present invention relates to a liposomal formulation for oral delivery of a bioactive agent that considers pH stability and oxidative stability of a bioactive ingredient. These lipid formulations are superior to conventional liposomes due to their stability, thereby circumventing the need for intra-venous delivery of bioactive agents. In one embodiment, the methods and compositions of the present invention relate to the oral delivery of insulin or a prodrug thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: The Penn State Research Foundation
    Inventors: Mark Kester, Karam El-Bayoumy, Christine Skibinski, Arunangshu Das
  • Patent number: 8680314
    Abstract: Provided are amino group-containing phosphorylcholine compound and a method for production thereof, that has a highly active amino group efficiently reactive with a wide variety of functional groups and the like under mild conditions, and is capable of introducing a phosphorylcholine-like group to various substrate surfaces to provide functionalities of the group. The amino group-containing phosphorylcholine compound of the present invention is represented by at least one of formulae (1) and (1?), and may be used as a compound, or a material thereof, capable of introducing a phosphorylcholine-like group to the surface of various substrates, such as medical instruments, cosmetics materials, and medicinal substances.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 25, 2014
    Assignee: NOF Corporation
    Inventors: Nobuyuki Yoshioka, Nobuyuki Sakamoto, Yosuke Matsuoka, Norio Iwakiri
  • Publication number: 20140051879
    Abstract: Novel biodegradable phosphoester polyamines are disclosed. The biodegradable phosphoester polyamines may be utilized as cross-linkers for sprayable compositions which may be used as tissue adhesives or sealants.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 20, 2014
    Applicant: Covidien LP
    Inventors: Nadya Belcheva, Ahmad Robert Hadba
  • Publication number: 20130345464
    Abstract: The present invention relates to I- and II-type crystals of L-?-glyceryl phosphoryl choline, and to a method for preparing same. More particularly, the present invention relates to noble I- and II-type anhydride crystals of L-?-glyceryl phosphoryl choline, which have a higher purity than conventional liquid L-?-glyceryl phosphoryl choline, and one advantage of which is that formulations and dosages of pharmaceuticals are easily modified, and another advantage of which is that the hygroscopicity of the crystals are much lower than that of conventional polymorphic crystals, providing excellent stability during storage. The present invention also relates to a method for preparing the I- and II-type crystals of L-?-glyceryl phosphoryl choline.
    Type: Application
    Filed: February 22, 2012
    Publication date: December 26, 2013
    Applicant: Hanseochem co., ltd
    Inventors: Min-Keun Oh, Ki-Nam Kim, Ki-Hyeong Seo, Dae-Gil Kwon
  • Publication number: 20130310591
    Abstract: Provided are amino group-containing phosphorylcholine compound and a method for production thereof, that has a highly active amino group efficiently reactive with a wide variety of functional groups and the like under mild conditions, and is capable of introducing a phosphorylcholine-like group to various substrate surfaces to provide functionalities of the group. The amino group-containing phosphorylcholine compound of the present invention is represented by at least one of formulae (1) and (1?), and may be used as a compound, or a material thereof, capable of introducing a phosphorylcholine-like group to the surface of various substrates, such as medical instruments, cosmetics materials, and medicinal substances.
    Type: Application
    Filed: December 22, 2011
    Publication date: November 21, 2013
    Applicant: NOF CORPORATION
    Inventors: Nobuyuki Yoshioka, Nobuyuki Sakamoto, Yosuke Matsuoka, Norio Iwakiri
  • Publication number: 20130303490
    Abstract: The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals.
    Type: Application
    Filed: December 12, 2011
    Publication date: November 14, 2013
    Applicant: Centre National De La Recherche Scientifique-CNRS
    Inventors: Vincent Francois, Pierre Corbeau, Charline Duquenne
  • Patent number: 8536362
    Abstract: The present invention provides ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs thereof that inhibit carnitine acyltransferases. The invention also provides compositions comprising these ?-hydroxy-?-aminophosphonates, ?-amino-?-aminophosphonates, and analogs, and methods of the use of such compounds and compositions in the treatment, amelioration or prevention of pathological conditions, diseases or disorders that are linked with fatty acid metabolism, such as non-insulin dependent diabetes or obesity. The invention also provides processes for the preparation of such compounds and compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: September 17, 2013
    Assignee: Nucitec S.A. de C.V.
    Inventors: Ricardo Abraham De La Cruz Cordero, Miguel Ångel Duarte Vázquez, Jorge Luis Rosado Loria
  • Publication number: 20130237720
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Application
    Filed: March 15, 2013
    Publication date: September 12, 2013
    Applicant: Vascular Biogenics Ltd.
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • Publication number: 20130209555
    Abstract: The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4?-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.
    Type: Application
    Filed: March 11, 2013
    Publication date: August 15, 2013
    Applicant: Vascular Biogenics Ltd.
    Inventor: Vascular Biogenics Ltd.
  • Publication number: 20130203707
    Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 8, 2013
    Applicant: Vascular Biogenics Ltd.
    Inventor: Vascular Biogenics Ltd.
  • Patent number: 8501715
    Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: August 6, 2013
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel, Niva Yacov, Eti Kovalevski-Ishai
  • Publication number: 20130172294
    Abstract: Unit dosage forms comprising between 1 mg and 100 mg VB-201 and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed herein, as well as treatment regimens comprising oral administration of VB-201 once or twice daily for treating an inflammatory disease or disorder.
    Type: Application
    Filed: January 5, 2011
    Publication date: July 4, 2013
    Applicant: Vascular Biogenics Ltd.
    Inventors: Yael Cohen, Naamit Sher, Itzhak Mendel, Niva Yacov, Eyal Breitbart
  • Patent number: 8445706
    Abstract: An unnatural amino acid including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A probe for detecting disease including a phosphate mimicking group for mimicking a phosphate group in phosphoamino acids and a protein phosphatase modifying group for covalently binding protein phosphatases. A method for detecting the presence of disease by administering the unnatural amino acid, binding the unnatural amino acid with a phosphatase, detecting a signal, and detecting the presence of disease. A method of identifying a known protein phosphatase, and a method of identifying an unknown protein phosphatase. A method of making the unnatural amino acid.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: May 21, 2013
    Assignee: Board of Trustees of Northern Illinois University
    Inventor: Kui Shen
  • Publication number: 20130079540
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Application
    Filed: November 9, 2012
    Publication date: March 28, 2013
    Inventors: Gideon HALPERIN, Eti Kovalevski-Ishai
  • Publication number: 20130065325
    Abstract: Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules.
    Type: Application
    Filed: May 18, 2011
    Publication date: March 14, 2013
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Anand Natrajan, David Sharpe, David Wen, Qingping Jiang
  • Publication number: 20130053470
    Abstract: New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform.
    Type: Application
    Filed: June 21, 2012
    Publication date: February 28, 2013
    Inventors: Fanny Raisin-Dadre, John E. Mckendrick, Alan Rhodes, Simon J. Onis, Shivpal S. Sandhu
  • Patent number: 8377910
    Abstract: The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine 1-phosphate (S1P), to be used as immunomodulators in a microbicidal treatment of infections derived from bacteria and specifically Mycobacterium tuberculosis. Such compounds are characterized in that they stimulate macrophagic Phospholipase D (PLD) (FIG. 1). The invention further relates to pharmaceutical compositions containing sphingosine derivative compounds and diagnostic methods for the preparation thereof. Further objects of the invention are methods of inducing or restoring the microbicidal activity in vitro of macrophages for monitoring the efficiency of phagocytosis and degradation processes performed by the same and assay methods suitable to evaluate therapeutic effectiveness of candidate microbicides.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: February 19, 2013
    Assignee: Universita Degli Studi di Roma “Tor Vergata”
    Inventors: Maurizio Fraziano, Sanjay Kumar Garg, Antonio Ciaramella, Giovanni Auricchio, Elisabetta Volpe, Angelo Martino, Patrizia Morena Baldihi, Paolo De Vito, Domenico Galati, Vittorio Colizzi
  • Publication number: 20120329758
    Abstract: Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.
    Type: Application
    Filed: January 5, 2011
    Publication date: December 27, 2012
    Inventors: Yael Cohen, Niva Yacov, Eyal Breitbart
  • Publication number: 20120277194
    Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
    Type: Application
    Filed: July 11, 2012
    Publication date: November 1, 2012
    Inventors: Rainer ALBERT, Eric FRANCOTTE, Frédéric ZECRI, Markus ZOLLINGER
  • Publication number: 20120264966
    Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.
    Type: Application
    Filed: November 23, 2011
    Publication date: October 18, 2012
    Inventors: Andrew David MILLER, Michael R. JORGENSEN, Rolf Kristian BERGE, Jon SKORVE
  • Publication number: 20120264719
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: September 20, 2010
    Publication date: October 18, 2012
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • Publication number: 20120238018
    Abstract: The invention relates to novel caged ceramide 1-phosphate (C1P) and the method of using them for delivering C1P intracellularly in vitro and in vivo, for research and therapeutic purposes.
    Type: Application
    Filed: October 26, 2010
    Publication date: September 20, 2012
    Applicant: Research Foundation of the City University of New york
    Inventors: Robert Bittman, Antonio Gomez Munoz
  • Publication number: 20120231972
    Abstract: The present invention relates to a probe compound that can comprise any substrate or metabolite of an enzymatic reaction in addition to an indicator component, such as, for example, a fluorescence dye, or the like. Moreover, the present invention relates to means for detecting enzymes in form of an array, which comprises any number of probe compounds of the invention which each comprise a different metabolite of interconnected metabolites representing the central pathways in all forms of life. Moreover, the present invention relates to a method for detecting enzymes involving the application of cell extracts or the like to the array of the invention which leads to reproducible enzymatic reactions with the substrates. These specific enzymatic reactions trigger the indicator (e.g. a fluorescence signal) and bind the enzymes to the respective cognate substrates. Moreover, the invention relates to means for isolating enzymes in form of nanoparticles coated with the probe compound of the invention.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 13, 2012
    Inventors: Peter N. Golyshin, Olga V. Golyshina, Kenneth N. Timmis, Tatyana Chernikova, Agnes Waliczek, Manuel Ferrer, Ana Beloqul, Maria E. Guazzaroni, Jose M. Vieltes, Florencio Pazos, Antonio Lopez De Lacey, Victor M. Fernandez
  • Publication number: 20120195861
    Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.
    Type: Application
    Filed: January 14, 2011
    Publication date: August 2, 2012
    Applicant: The General Hospital Corporation
    Inventors: Jonathan L. Tilly, Joshua Johnson
  • Patent number: 8222443
    Abstract: A phosphorylcholine group-containing compound that is a structure having a phosphorylcholine group represented by the following formula 1 and an amino group or a group derived from an amino group in an identical compound. (In the formula, m is 2 or more and 6 or less and p is 1 or 2. Each of X1, X2 and X3 is an alkyl group whose carbon number is 1 or more and 6 or less.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: July 17, 2012
    Assignee: Shiseido Company, Ltd.
    Inventors: Kazuyuki Miyazawa, Yukimitsu Suda
  • Publication number: 20120157370
    Abstract: The invention relates to the use of radical traps in detergents and cleaners in order to improve cleaning performance, in particular for dirt containing polymerizable dyes.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 21, 2012
    Applicant: Henkel AG & Co. KGaA
    Inventors: Christian Kropf, Andreas Buhl, André Hätzelt
  • Publication number: 20120128536
    Abstract: The present disclosure relates to a molecularly imprinted structure for detection of a pentraxin protein and a method for preparing the same by synthesizing a reactive group-pentraxin protein ligand complex specifically reacting with the pentraxin protein and being polymerizable with a crosslink agent to detect a pentraxin protein by using the complex. The present disclosure also provides a chip for detection of a C-reactive protein and a method for preparing the same, the chip including a molecularly imprinted layer having excellent sensitivity to a C-reactive protein and an improved binding force to a metal substrate by using click chemistry.
    Type: Application
    Filed: November 16, 2011
    Publication date: May 24, 2012
    Applicant: Daegu Gyeongbuk Institute of Science and Technology
    Inventors: Sang Won Jeong, Eun Joo Kim, Hyun-Chul Kim, Se Geun Lee, Sung Jun Lee
  • Patent number: 8158611
    Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: April 17, 2012
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
  • Patent number: 8148559
    Abstract: Disclosed are processes for development and recovery of lipids from biomass. A plant or microorganism-based biomass can be developed to encourage a desired lipid profile. Following development, ecologically friendly normally gaseous fluids such as carbon dioxide can be pressurized to a supercritical state followed by rapid expansion. The fluid is first contacted with a biomass source including oil-containing microorganisms and/or agricultural products. For instance, fungi or algae can be bioconverted from another biomass sources such as canola seed or corn syrup and then contacted with the high pressure fluid. During a contact period, the fluid can diffuse into the biomass, and in particular through the cell walls of the biomass. The fluid undergoes rapid release of pressure and opens the cell structure for improved release of oil. The fluid can optionally be utilized for extraction following the explosion process. For instance, the fluid can be re-pressurized in the same vessel for extraction processes.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: April 3, 2012
    Assignee: Clemson University Research Foundation
    Inventors: Terry H. Walker, Meidui Dong, Keri B. Cantrell, Mark C. Thies
  • Patent number: 8129557
    Abstract: A phosphonic acid diester derivative represented by the following general formula (1): wherein at least one of R1 and R2 denotes a leaving group.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: March 6, 2012
    Inventors: Jun Hiratake, Kanzo Sakata, Liyou Han
  • Publication number: 20120004439
    Abstract: Disclosed is a composition for prevention and treatment of alopecia or for hair growth, comprising a phytosphingosine-1-phosphate derivative or a pharmaceutically acceptable salt thereof as an active ingredient. Also, a medicine comprising the composition and a quasi-drug comprising the composition are provided.
    Type: Application
    Filed: July 30, 2009
    Publication date: January 5, 2012
    Inventors: Myeong Jun Choi, Joo Hyun Cho
  • Publication number: 20110306133
    Abstract: Disclosed are a culture medium, an additive, and a method for efficiently inducing the differentiation of mammalian somatic stem cells into cells having the characteristics of adipocytes under conditions of serum-free or low-serum culture medium. The culture medium for inducing the differentiation of mammalian somatic stem cells into adipocytes comprises a basal medium for culturing mammalian cells, an agent for inducing the differentiation of mammalian somatic stem cells into adipocytes, biotin, a ligand for endothelial cell differentiation gene (Edg) family receptors, vitamin C, and HEPES, which culture medium is serum-free or contains a low concentration of serum.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 15, 2011
    Inventor: Yoshiyuki Hotta
  • Publication number: 20110294869
    Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.
    Type: Application
    Filed: September 23, 2009
    Publication date: December 1, 2011
    Applicant: Traversa Therapeutics, Inc.
    Inventor: Scott G. Petersen
  • Patent number: 8063238
    Abstract: Highly polymerizable diamine compounds having a phosphorylcholine group are disclosed. High-molecular weight polymers are obtained from the highly polymerizable diamine compound having a phosphorylcholine group as a monomer, and the polymers have improved mechanical strength, water resistance and heat resistance while maintaining excellent biocompatibility and processability of MPC polymers. Processes for producing the polymers are disclosed. The diamine compounds having a phosphorylcholine group are represented by Formula (I). The polymers contain at least 1 mol % of a specific structural unit with a phosphorylcholine group represented by Formula (II) and have a number average molecular weight of not less than 5,000. In the processes, the diamine compound is used as a monomer.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: November 22, 2011
    Assignees: Tokai University Educational System, Tokyo Medical and Dental University
    Inventors: Yu Nagase, Naoya Shimoyamada, Yasuhiko Iwasaki, Kazuhiko Ishihara
  • Patent number: 8022238
    Abstract: A compound of Formula 1 Rf-A-OP(O)(O?M+)(OROH)??Formula 1 wherein Rf is a C2 to C6 linear or branched perfluoroalkyl optionally interrupted by one, two or three ether oxygen atoms; A is (CH2CF2)m(CH2)n—, (CH2)oSO2N(CH3)(CH2)p—, O(CF2)q(CH2)r—, or OCHFCF2OE-; m is 0 to 4; n, o, p, and r are each independently 2 to 20; q is 2; E is a C2 to C20 linear or branched alkyl group optionally interrupted by oxygen, sulfur, or nitrogen atoms; a cyclic alkyl group, or a C6 to C10 aryl group; M is H or a Group I metal or an ammonium cation (NHxR2y)+ wherein R2 is a C1 to C4 alkyl, x is 0 to 4, y is 0 to 4 and x+y is 4; and R is a C2 to C60 linear or branched alkyl group optionally interrupted by hetero atoms selected from the group consisting of an oxygen, sulfur, or nitrogen atom; a cyclic alkyl; or a C6 to C10 aryl; provided that when R is greater than 8 carbons, the ratio of hetero atoms to carbon atoms is at least 1:2.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: September 20, 2011
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Sheng Peng, Allison Mary Yake
  • Publication number: 20110213061
    Abstract: The invention relates to a method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the thus obtained alkylphosphonic acid, salt or ester (II) thereof is reacted with acetylenic compounds of formula (V) to yield a mono-functionalized dialkylphosphinic acid derivative (VI) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivative (VI) is reacted with a hydrogen cyanide source to yield a mono-functionalized dialkylphosphinic acid derivative (VII) in the presence of a catalyst C, and d) the thus obtained mono-functionalized dialkylphosphinic acid derivative (VII); is reacted to yield a mono-aminofunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst D or a reduction agent, wherein R1, R2, R3, R4, R5, R6 are the
    Type: Application
    Filed: October 6, 2009
    Publication date: September 1, 2011
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Michael Hill, Werner Krause, Martin Sicken
  • Publication number: 20110212088
    Abstract: Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Inventors: Roger A. SABBADINI, Jonathan Michael WOJCIAK
  • Publication number: 20110189212
    Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
    Type: Application
    Filed: April 13, 2011
    Publication date: August 4, 2011
    Applicant: Vascular Biogenics Ltd.
    Inventors: Dror HARATS, Jacob George, Gideon Halperin, Itzhak Mendel, Niva Yacov, Eti Kovalevski-Ishai
  • Publication number: 20110152218
    Abstract: The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 23, 2011
    Inventor: Derek Woodcock
  • Patent number: 7910626
    Abstract: The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: March 22, 2011
    Assignee: Novartis AG
    Inventors: Volker Brinkmann, Gilles Feutren, Robert Paul Hof
  • Patent number: 7902176
    Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: March 8, 2011
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
  • Patent number: 7893286
    Abstract: Disclosed are improved methods for the synthesis of phospholipid ether analogs and alkyl phosphocholine analogs. The methods allow greater versatility of the reactants used and greater ease in synthesizing alkyl chains of varying length while affording reaction temperatures at room temperature or below. The methods disclosed herein provide reactants and conditions using alkyl halides and organozinc reagents and do not utilize Gringard reactions thus, allowing greater ease of their separation and purity of products. The PLE compounds synthesized by the methods disclosed herein can also be used for synthesizing high specific activity phospholipid ether (PLE) analogs, for use in treatment and diagnosis of cancer.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 22, 2011
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino
  • Patent number: 7893291
    Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: February 22, 2011
    Assignee: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
  • Patent number: RE42275
    Abstract: Compounds of the formula, A—L—B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: April 5, 2011
    Assignee: Cancer Targeted Technology LLC
    Inventor: Clifford E. Berkman